User banner image
User avatar
  • Michael SCHWARZ

Publications:

Schwarz C; Chromy D; Bangert C; Schwarz M; Jachs M; Reiberger T; Gschwantler M, 2022. Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV/HDV-associated compensated cirrhosis.  J Hepatol.

Semmler G; Meyer EL; Kozbial K; Schwabl P; Hametner-Schreil S; Zanetto A; Bauer D; Chromy D; Simbrunner B; Scheiner B; Stättermayer AF; Pinter M; Schöfl R; Russo FP; Greenfield H; Schwarz M; Schwarz C; Gschwantler M; Alonso López S; Manzano ML; Ahumada A; Bañares R; Pons M; Rodríguez-Tajes S; Genescà J; Lens S; Trauner M; Ferenci P; Reiberger T; Mandorfer M, 2022. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.  J Hepatol 76(4):812-821

Schmidbauer C; Chromy D; Schmidbauer VU; Schwarz M; Jachs M; Bauer DJM; Binter T; Apata M; Nguyen DT; Mandorfer M; Simbrunner B; Rieger A; Mayer F; Breuer M; Strassl R; Schmidt R; Holzmann H; Trauner M; Gschwantler M; Reiberger T, 2021. Epidemiological trends of HBV and HDV coinfection among Viennese HIV+ patients.  Liver Int 41(11):2622-2634

Schmidbauer C; Schwarz M; Schütz A; Schubert R; Schwanke C; Gutic E; Pirker R; Lang T; Reiberger T; Haltmayer H; Gschwantler M, 2021. Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy.  PLoS One 16(6):e0252274

Publication list retrieved from NCBI using ImpactPubs

.